Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Lewis

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Proceedings of the National Academy of Sciences of the United States of America|July 27, 2007
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytesDavid B Rozema, David L Lewis, Darren H Wakefield, et al.
Nucleic Acids Research|September 2, 2006
Transcriptional and phenotypic comparisons of Ppara knockout and siRNA knockdown miceAngus T De Souza, Xudong Dai, Andrew G Spencer, et al.
Molecular Cancer Therapeutics|October 29, 2017
HIF2α-Targeted RNAi Therapeutic Inhibits Clear Cell Renal Cell CarcinomaSo C Wong, Weijun Cheng, Holly Hamilton, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 27, 2013
Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infectionChristine I Wooddell, David B Rozema, Markus Hossbach, et al.
Science Translational Medicine|September 29, 2017
RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAgChristine I Wooddell, Man-Fung Yuen, Henry Lik-Yuen Chan, et al.
JCI Insight|May 8, 2020
Development of an RNAi therapeutic for alpha-1-antitrypsin liver diseaseChristine I Wooddell, Keith Blomenkamp, Ryan M Peterson, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 19, 2015
Protease-triggered siRNA delivery vehiclesDavid B Rozema, Andrei V Blokhin, Darren H Wakefield, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Proceedings of the National Academy of Sciences of the United States of America|July 27, 2007
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytesDavid B Rozema, David L Lewis, Darren H Wakefield, et al.
Nucleic Acids Research|September 2, 2006
Transcriptional and phenotypic comparisons of Ppara knockout and siRNA knockdown miceAngus T De Souza, Xudong Dai, Andrew G Spencer, et al.
Molecular Cancer Therapeutics|October 29, 2017
HIF2α-Targeted RNAi Therapeutic Inhibits Clear Cell Renal Cell CarcinomaSo C Wong, Weijun Cheng, Holly Hamilton, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 27, 2013
Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infectionChristine I Wooddell, David B Rozema, Markus Hossbach, et al.
Science Translational Medicine|September 29, 2017
RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAgChristine I Wooddell, Man-Fung Yuen, Henry Lik-Yuen Chan, et al.
JCI Insight|May 8, 2020
Development of an RNAi therapeutic for alpha-1-antitrypsin liver diseaseChristine I Wooddell, Keith Blomenkamp, Ryan M Peterson, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 19, 2015
Protease-triggered siRNA delivery vehiclesDavid B Rozema, Andrei V Blokhin, Darren H Wakefield, et al.
Pageof 4